March 30, 2004

Skinvisible Sells Exclusive Rights for $1 Million for the North American Marketing and Distribution Rights to Its Patented Antimicrobial Hand Sanitizer

LAS VEGAS, Mar 30, 2004 /PRNewswire-FirstCall via COMTEX/ --

Skinvisible, Inc. (OTC Bulletin Board: SKVI) (Website: www.skinvisible.com) announced today that Dermal Defense, Inc. (www.dermaldefense.com) a Preferred Account has signed a 'Letter of Intent'(LOI) to acquire the exclusive marketing and distribution rights to its patented Antimicrobial Hand Sanitizer product for North America.

Terms of the LOI require Dermal Defense to pay a fee of $1 million comprising of a non-refundable deposit of $250,000 with the balance of $750,000 payable as to $75,000 per calendar quarter or 5% of product sales (whichever is greater) until the entire $750,000 is received. The deposit of $250,000 has been received by Skinvisible. In addition and further to the payment fee of $1 million Dermal Defense agrees to pay a royalty fee of 5% on product sales of the Antimicrobial Hand Sanitizer.

Mr. James Graves, President of Dermal Defense, Inc. states that 'since the successful introduction of the Hand Sanitizer with our distributor Galls, Inc. (see press releases of Oct 7/03 &Dec 17/03) it became apparent that we had to have the exclusive rights to this product.'Galls, Inc. (www.galls.com) is the largest distributor of public safety equipment in the United States selling products to law enforcement, fire, rescue and EMS as well as the military. Dermal Defense is their first product to be offered in the fight to 'Stop the Spread of Infection'through hand contact. In addition, Dermal Defense has commenced a new packaging design for product sales, which will commence this fall through retail stores.

Independent studies indicate that the Dermal Defense formulation offers significant advantages over alcohol-based sanitizers marketed to kill bacteria and viruses on the hands. The Dermal Defense formulation offers continuous protection, long-term kill of up to 4 hours per application, undiminished by hand washing or perspiration. In comparison, the alcohol gels provide instant protection but offer no long-term persistence.

'This Agreement allows us the opportunity to stay focused on the research and development of new polymer technologies and formulations while providing a steady stream of revenue from product sales and royalties,'says Mr. Terry Howlett, Skinvisible's President. 'It makes the most sense for us to gain product exposure through a company which understands marketing.'

Headquartered in Las Vegas, Nevada, Skinvisible, Inc. is focused on the development of innovative topical polymer-based delivery systems and related technologies incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymers into stable water emulsions. Skinvisible's primary marketing and sales objectives are to license its technologies and/or sell its delivery systems to provide enhanced product performance for established brand manufacturers and providers of prescription, over-the-counter, cosmetic, and skincare products. In addition Skinvisible formulates and manufactures products for private label customers.

This press release contains 'forward looking'statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934 as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports that will be on file with the US Securities and Exchange Commission (including but not limited to the report on Form 10-QSB for the quarter ending September 30, 2003).

For Corp. Info. Contact: T. Howlett - Skinvisible, Inc. - Ph. (702) 433-7154 / Fax (702) 433-7192 / Email: terry@skinvisible.com. For Media Info. Contact: Tommi Hanley - Thompson Lloyd Communications - Ph. (250) 860-9959 / Email: tommi.tlc@shaw.ca.

SOURCE Skinvisible, Inc.

T. Howlett of Skinvisible, Inc., +1-702-433-7154, or fax,+1-702-433-7192, terry@skinvisible.com, or Tommi Hanley of Thompson LloydCommunications, +1-250-860-9959, tommi.tlc@shaw.ca, for Skinvisible, Inc./Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20030416/LAW068LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.com

Press Release Index

New Press Release Alerts:

If you are interested in receiving corporate and new product development news from Skinvisible, simply enter your email address below.